Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients.

Hoang JM, Upadhyay N, Dike DN, Lee J, Johnson ML, Cleeland CS, Mendoza T, Chen H, Trivedi MV.

Support Care Cancer. 2019 Jul 23. doi: 10.1007/s00520-019-05004-8. [Epub ahead of print]

PMID:
31338641
2.

Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial.

Wang XS, Shi Q, Bhadkamkar NA, Cleeland CS, Garcia-Gonzalez A, Aguilar JR, Heijnen C, Eng C.

J Pain Symptom Manage. 2019 Jun 26. pii: S0885-3924(19)30362-8. doi: 10.1016/j.jpainsymman.2019.06.018. [Epub ahead of print]

PMID:
31254639
3.

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).

Mendoza TR, Williams LA, Keating KN, Siegel J, Elbi C, Nowak AK, Hassan R, Cuffel B, Cleeland CS.

J Patient Rep Outcomes. 2019 Jun 17;3(1):34. doi: 10.1186/s41687-019-0122-5.

4.

Improving attribution of adverse events in oncology clinical trials.

George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS.

Cancer Treat Rev. 2019 Jun;76:33-40. doi: 10.1016/j.ctrv.2019.04.004. Epub 2019 Apr 25. Review.

PMID:
31108240
5.

Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial.

Gunn GB, Mendoza TR, Garden AS, Wang XS, Shi Q, Morrison WH, Frank SJ, Phan J, Fuller CD, Chambers MS, Hanna EY, Lu C, Rosenthal DI, Cleeland CS.

Support Care Cancer. 2019 Apr 29. doi: 10.1007/s00520-019-04791-4. [Epub ahead of print]

PMID:
31037378
6.

Interpreting Patient-reported Outcome Scores for Clinical Research and Practice: Definition, Determination, and Application of Cutpoints.

Shi Q, Mendoza TR, Cleeland CS.

Med Care. 2019 May;57 Suppl 5 Suppl 1:S8-S12. doi: 10.1097/MLR.0000000000001062.

PMID:
30985590
7.

Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN).

Wang XS, Shi Q, Williams LA, Cleeland CS, Garcia-Gonzalez A, Chen TY, Shahid DR, Ramirez PT, Iniesta MD, Siverand AM, Meyer LA.

Gynecol Oncol. 2019 Mar;152(3):492-500. doi: 10.1016/j.ygyno.2018.11.004.

PMID:
30876494
8.

Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study.

George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS.

J Med Internet Res. 2019 Mar 14;21(3):e10348. doi: 10.2196/10348.

9.

Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study.

Mendoza TR, Kehl KL, Bamidele O, Williams LA, Shi Q, Cleeland CS, Simon G.

Support Care Cancer. 2019 Sep;27(9):3439-3447. doi: 10.1007/s00520-018-4632-0. Epub 2019 Jan 19.

PMID:
30661202
10.

Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center.

George GC, Buford A, Hess K, Piha-Paul SA, Zinner R, Subbiah V, Hinojosa C, Cleeland CS, Meric-Bernstam F, Bernstam EV, Hong DS.

JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00030.

11.

Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).

Williams LA, Whisenant MS, Mendoza TR, Haq S, Keating KN, Cuffel B, Cleeland CS.

Qual Life Res. 2018 Dec;27(12):3229-3241. doi: 10.1007/s11136-018-1982-5. Epub 2018 Sep 5. Review.

PMID:
30187393
12.

Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS).

Williams LA, Garcia-Gonzalez A, Mendoza TR, Haq S, Cleeland CS.

Support Care Cancer. 2019 Mar;27(3):1021-1028. doi: 10.1007/s00520-018-4391-y. Epub 2018 Aug 10.

PMID:
30094731
13.

Removal and insertion of central venous catheters in cancer patients is associated with high symptom burden.

Raad S, Chaftari AM, Hachem RY, Shah P, Natividad E, Cleeland CS, Rosenblatt J.

Expert Rev Med Devices. 2018 Aug;15(8):591-596. doi: 10.1080/17434440.2018.1500892. Epub 2018 Aug 1.

PMID:
30067125
14.

Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study.

Yue J, Shi Q, Xu T, Jeter M, Chen TY, Komaki R, Gomez DR, Pan T, Cleeland CS, Liao Z, Wang XS.

Qual Life Res. 2018 Jun;27(6):1563-1570. doi: 10.1007/s11136-018-1834-3. Epub 2018 Mar 16.

15.

Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma.

Shah N, Shi Q, Giralt S, Williams L, Bashir Q, Qazilbash M, Champlin RE, Cleeland CS, Wang XS.

Qual Life Res. 2018 Apr;27(4):979-985. doi: 10.1007/s11136-017-1759-2. Epub 2017 Dec 19.

PMID:
29260444
16.

Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old.

MD Anderson Head and Neck Cancer Symptom Working Group, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Brandon Gunn G.

Radiat Oncol. 2017 Nov 23;12(1):186. doi: 10.1186/s13014-017-0921-x.

17.

The contribution of pain in determining the health status of cancer patients with bone metastases: A secondary analysis of data from three Phase III registration trials.

Mendoza TR, Dueck AC, Shi Q, Ma H, Zhang J, Qian Y, Cleeland CS.

Eur J Pain. 2018 Mar;22(3):565-571. doi: 10.1002/ejp.1139. Epub 2017 Oct 30.

PMID:
29082574
18.

Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old.

MD Anderson Head and Neck Cancer Symptom Working Group, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Gunn GB.

Radiat Oncol. 2017 Sep 9;12(1):150. doi: 10.1186/s13014-017-0878-9. Erratum in: Radiat Oncol. 2017 Nov 23;12 (1):186.

19.

Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.

Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, Li Y, Castro KM, Denicoff A, Rogak LJ, Piekarz RL, Cleeland CS, Sloan JA, Schrag D, Basch E.

Clin Trials. 2017 Jun;14(3):255-263. doi: 10.1177/1740774517698645. Epub 2017 Mar 20.

20.

Validation of the Persian Version of the Brief Pain Inventory (BPI-P) in Chronic Pain Patients.

Majedi H, Dehghani SS, Soleyman-Jahi S, Emami Meibodi SA, Mireskandari SM, Hajiaghababaei M, Tafakhori A, Mendoza TR, Cleeland CS.

J Pain Symptom Manage. 2017 Jul;54(1):132-138.e2. doi: 10.1016/j.jpainsymman.2017.02.017. Epub 2017 May 4.

PMID:
28479416
21.

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ.

Ann Hematol. 2017 Jun;96(6):977-985. doi: 10.1007/s00277-017-2980-3. Epub 2017 Mar 23.

22.

Determination of mild, moderate, and severe pain interference in patients with cancer.

Shi Q, Mendoza TR, Dueck AC, Ma H, Zhang J, Qian Y, Bhowmik D, Cleeland CS.

Pain. 2017 Jun;158(6):1108-1112. doi: 10.1097/j.pain.0000000000000890.

PMID:
28267060
23.

Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials.

George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS.

Cancer. 2016 Nov 15;122(21):3401-3409. doi: 10.1002/cncr.30182. Epub 2016 Jul 14.

24.

Validity and Reliability of the Indonesian Version of the Brief Fatigue Inventory in Cancer Patients.

Paramita N, Nusdwinuringtyas N, Nuhonni SA, Atmakusuma TD, Ismail RI, Mendoza TR, Cleeland CS.

J Pain Symptom Manage. 2016 Nov;52(5):744-751. doi: 10.1016/j.jpainsymman.2016.04.011. Epub 2016 Sep 19.

PMID:
27660081
25.

Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer.

Shi Q, Mendoza TR, Wang XS, Cleeland CS.

Eur J Cancer. 2016 Nov;67:83-90. doi: 10.1016/j.ejca.2016.07.027. Epub 2016 Sep 9.

PMID:
27620946
26.

The utility of patient-reported outcome measures among patients with myalgic encephalomyelitis/chronic fatigue syndrome.

Murdock KW, Wang XS, Shi Q, Cleeland CS, Fagundes CP, Vernon SD.

Qual Life Res. 2017 Apr;26(4):913-921. doi: 10.1007/s11136-016-1406-3. Epub 2016 Sep 6.

27.

Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer.

Shi Q, Wang XS, Vaporciyan AA, Rice DC, Popat KU, Cleeland CS.

J Pain Symptom Manage. 2016 Dec;52(6):822-831. doi: 10.1016/j.jpainsymman.2016.07.005. Epub 2016 Aug 10.

28.

Validity and reliability of a Turkish Brief Pain Inventory Short Form when used to evaluate musculoskeletal pain.

Celik EC, Yalcinkaya EY, Atamaz F, Karatas M, Ones K, Sezer T, Eren I, Paker N, Gning I, Mendoza T, Cleeland CS.

J Back Musculoskelet Rehabil. 2017;30(2):229-233. doi: 10.3233/BMR-160738.

PMID:
27472857
29.

Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes.

Sio TT, Lin HK, Shi Q, Gunn GB, Cleeland CS, Lee JJ, Hernandez M, Blanchard P, Thaker NG, Phan J, Rosenthal DI, Garden AS, Morrison WH, Fuller CD, Mendoza TR, Mohan R, Wang XS, Frank SJ.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1107-14. doi: 10.1016/j.ijrobp.2016.02.044. Epub 2016 Feb 18.

30.

Enhancing quality of life as a goal for anticancer therapeutics.

Pettit SD, Lipshultz SE, Cleeland CS, Roberts S, Davis M, Berridge BR, Kirch RA.

Sci Transl Med. 2016 Jun 22;8(344):344ed9. doi: 10.1126/scitranslmed.aag0382.

PMID:
27334258
31.

Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module.

Gunn GB, Atalar B, Mendoza TR, Cleeland CS, Selek U, Özyar E, Rosenthal DI.

Balkan Med J. 2016 May;33(3):339-43. doi: 10.5152/balkanmedj.2015.150148. Epub 2016 May 1.

32.

Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy.

Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z.

J Pain Symptom Manage. 2016 May;51(5):832-8. doi: 10.1016/j.jpainsymman.2015.12.316. Epub 2016 Feb 16.

33.

Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.

Wang XS, Shi Q, Dougherty PM, Eng C, Mendoza TR, Williams LA, Fogelman DR, Cleeland CS.

Oncology. 2016;90(3):127-35. doi: 10.1159/000443377. Epub 2016 Feb 17.

34.

[Properties of the Measures to Assess Oxaliplatin-induced Peripheral Neuropathy: A Literature Review].

Chu SH, Lee YJ, Lee YJ, Cleeland CS.

J Korean Acad Nurs. 2015 Dec;45(6):783-801. doi: 10.4040/jkan.2015.45.6.783. Review. Korean.

PMID:
26805492
35.

The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative.

Zikos E, Coens C, Quinten C, Ediebah DE, Martinelli F, Ghislain I, King MT, Gotay C, Ringash J, Velikova G, Reeve BB, Greimel E, Cleeland CS, Flechtner H, Taphoorn MJ, Weis J, Schmucker-von Koch J, Sprangers MA, Bottomley A; EORTC PROBE.

J Natl Cancer Inst. 2015 Dec 28;108(5). pii: djv391. doi: 10.1093/jnci/djv391. Print 2016 May. Review.

36.

Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study.

Tevaarwerk AJ, Lee JW, Terhaar A, Sesto ME, Smith ML, Cleeland CS, Fisch MJ.

Cancer. 2016 Feb 1;122(3):438-46. doi: 10.1002/cncr.29656. Epub 2015 Dec 21.

37.

Patient-Reported Outcomes Accurately Measure the Value of an Enhanced Recovery Program in Liver Surgery.

Day RW, Cleeland CS, Wang XS, Fielder S, Calhoun J, Conrad C, Vauthey JN, Gottumukkala V, Aloia TA.

J Am Coll Surg. 2015 Dec;221(6):1023-30.e1-2. doi: 10.1016/j.jamcollsurg.2015.09.011. Epub 2015 Oct 21.

PMID:
26611799
38.

Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study.

Gunn GB, Hansen CC, Garden AS, Fuller CD, Mohamed AS, Morrison WH, Frank SJ, Beadle BM, Phan J, Chronowski GM, Sturgis EM, Lewis CM, Lu C, Hutcheson KA, Mendoza TR, Cleeland CS, Rosenthal DI.

Radiother Oncol. 2015 Oct;117(1):132-8. doi: 10.1016/j.radonc.2015.09.007. Epub 2015 Sep 21.

39.

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E; National Cancer Institute PRO-CTCAE Study Group.

JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639. Erratum in: JAMA Oncol. 2016 Jan;2(1):146.

40.

Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis.

Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SA.

Biol Blood Marrow Transplant. 2016 Feb;22(2):226-231. doi: 10.1016/j.bbmt.2015.07.036. Epub 2015 Aug 5.

41.

Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale.

Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS.

J Pain. 2015 Oct;16(10):1032-43. doi: 10.1016/j.jpain.2015.07.002. Epub 2015 Jul 22.

42.

Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory.

Fagundes CP, Shi Q, Vaporciyan AA, Rice DC, Popat KU, Cleeland CS, Wang XS.

J Thorac Cardiovasc Surg. 2015 Sep;150(3):613-9.e2. doi: 10.1016/j.jtcvs.2015.05.057. Epub 2015 May 28.

43.

Symptom management of gynecologic cancers: refocusing on the forest.

Cleeland CS, Rose SL.

Gynecol Oncol. 2015 Mar;136(3):413-4. doi: 10.1016/j.ygyno.2015.01.555. No abstract available.

PMID:
25752571
44.

Automated pain intervention for underserved minority women with breast cancer.

Anderson KO, Palos GR, Mendoza TR, Cleeland CS, Liao KP, Fisch MJ, Garcia-Gonzalez A, Rieber AG, Nazario LA, Valero V, Hahn KM, Person CL, Payne R.

Cancer. 2015 Jun 1;121(11):1882-90. doi: 10.1002/cncr.29204. Epub 2015 Feb 24.

45.

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents.

Patrick DL, Cleeland CS, von Moos R, Fallowfield L, Wei R, Öhrling K, Qian Y.

Support Care Cancer. 2015 Apr;23(4):1157-68. doi: 10.1007/s00520-014-2525-4. Epub 2014 Dec 23. Review.

PMID:
25533578
46.

Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis.

Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, Mendoza TR, Cleeland CS.

Cancer. 2015 Apr 1;121(7):1138-46. doi: 10.1002/cncr.29154. Epub 2014 Dec 2.

47.

The symptom burden of treatment-naive patients with head and neck cancer.

Hanna EY, Mendoza TR, Rosenthal DI, Gunn GB, Sehra P, Yucel E, Cleeland CS.

Cancer. 2015 Mar 1;121(5):766-73. doi: 10.1002/cncr.29097. Epub 2014 Nov 4.

48.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D.

J Natl Cancer Inst. 2014 Sep 29;106(9). pii: dju244. doi: 10.1093/jnci/dju244. Print 2014 Sep.

49.

Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.

Chu SH, Lee YJ, Lee ES, Geng Y, Wang XS, Cleeland CS.

Support Care Cancer. 2015 Feb;23(2):513-24. doi: 10.1007/s00520-014-2408-8. Epub 2014 Sep 26. Review.

PMID:
25256375
50.

Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma.

Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ.

Leuk Lymphoma. 2015 May;56(5):1335-41. doi: 10.3109/10428194.2014.956313. Epub 2014 Nov 20.

Supplemental Content

Loading ...
Support Center